ANI Pharmaceuticals (ANIP) EPS Estimated At $0.79; Neonode Has 0.62 Sentiment

July 17, 2017 - By Adrian Erickson

Neonode Inc., formerly SBE, Inc., develops and licenses user interfaces and optical infrared touch solutions. The company has market cap of $55.19 million. The Company’s technology offers multiple features, including the ability to sense an object’s size, depth, velocity, pressure and proximity to any type of surface. It currently has negative earnings. It operates through the touch technology licensing business segment.

Analysts expect ANI Pharmaceuticals Inc (NASDAQ:ANIP) to report $0.79 EPS on August, 3.They anticipate $0.20 EPS change or 20.20% from last quarter’s $0.99 EPS. ANIP’s profit would be $9.12M giving it 15.21 P/E if the $0.79 EPS is correct. After having $0.62 EPS previously, ANI Pharmaceuticals Inc’s analysts see 27.42% EPS growth. About 41,298 shares traded. ANI Pharmaceuticals Inc (NASDAQ:ANIP) has declined 0.02% since July 17, 2016 and is downtrending. It has underperformed by 16.72% the S&P500.

About 36,119 shares traded. Neonode, Inc (NEON) has declined 22.81% since July 17, 2016 and is downtrending. It has underperformed by 39.51% the S&P500.

Awm Investment Company Inc. holds 1.32% of its portfolio in Neonode, Inc for 3.67 million shares. Essex Investment Management Co Llc owns 696,000 shares or 0.21% of their US portfolio. Moreover, Lincoln Capital Llc has 0.21% invested in the company for 163,700 shares. The California-based Menta Capital Llc has invested 0.02% in the stock. Parkside Financial Bank & Trust, a Missouri-based fund reported 10,521 shares.

Investors sentiment decreased to 1.05 in Q4 2016. Its down 1.28, from 2.33 in 2016Q3. It dived, as 25 investors sold ANI Pharmaceuticals Inc shares while 41 reduced holdings. 16 funds opened positions while 53 raised stakes. 6.22 million shares or 6.47% more from 5.84 million shares in 2016Q3 were reported. Prudential Fincl stated it has 13,880 shares. 4,874 were reported by Nationwide Fund Advsr. Bancorporation Of Ny Mellon Corporation accumulated 163,354 shares or 0% of the stock. 33,126 are owned by Rice Hall James & Associate Lc. Tudor Inv Et Al, a Connecticut-based fund reported 4,600 shares. 9,953 were accumulated by Kbc Grp Incorporated Nv. Consonance Capital Management Limited Partnership holds 3.27% or 491,608 shares in its portfolio. Violich Management Inc holds 4,020 shares. Citigroup holds 0% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 23,282 shares. Tower Rech Cap Ltd Liability (Trc) invested in 0% or 83 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 235 shares stake. Georgia-based Invesco Limited has invested 0% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Creative Planning owns 0% invested in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 467 shares. Alliancebernstein L P invested in 0% or 56,250 shares. Blackrock Group Inc Ltd invested in 0% or 14,066 shares.

Among 5 analysts covering ANI Pharma (NASDAQ:ANIP), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. ANI Pharma had 14 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) has “Strong Buy” rating given on Thursday, June 23 by Raymond James. The firm has “Buy” rating by TheStreet given on Wednesday, September 2. As per Monday, September 28, the company rating was upgraded by TH Capital. The firm earned “Hold” rating on Tuesday, May 24 by Standpoint Research. As per Wednesday, February 22, the company rating was downgraded by TH Capital. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) has “Neutral” rating given on Tuesday, August 4 by TH Capital. As per Monday, September 28, the company rating was upgraded by Roth Capital. The company was upgraded on Tuesday, July 19 by Oppenheimer. The firm has “Outperform” rating by Oppenheimer given on Friday, August 5. On Friday, November 13 the stock rating was initiated by Standpoint Research with “Buy”.

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The company has market cap of $554.40 million. The Firm is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. It has a 150.02 P/E ratio. The Firm focuses on areas, including controlled substances, anti-cancer , hormones and steroids, and complex formulations.